Building a Clinical Operations Function in Biotech: Where Hiring Managers Go Wrong

The timing problem no one talks about until it's too late

Most biotech hiring managers don't start thinking seriously about building a clinical operations function until a trial is already in motion. By that point, the hire isn't strategic, it's reactive. The person you bring in isn't setting up the function; they're catching up with it. That shift in context changes everything: the quality of candidates you can attract, the onboarding time they'll need, and the infrastructure gaps they'll be walking into. Building a clinical operations team in biotech is a fundamentally different challenge to filling a vacancy, and companies that treat it as the latter tend to pay for it in ways that compound.

This matters more now than it might appear from the outside. Biopharma layoffs rose 16% year-on-year in 2025, and the natural assumption is that a larger available pool makes clinical operations hiring easier. In practice, it doesn't, at least not in the way that matters for a growth-stage biotech.

‍

Why a softer market doesn't solve your hiring problem

The candidates released from big pharma restructures and CRO consolidations are, on the whole, experienced. Some are genuinely strong. But availability and fit aren't the same thing, and in clinical operations the gap between them is particularly sharp.

Experienced CRAs and SCRAs with strong CVs remain in high demand, and the candidates worth hiring are often fielding multiple approaches. Those with biotech-specific sponsor-side experience, where the function is lean, the infrastructure is limited, and there's no established playbook to follow, are a subset of that group, and a smaller one than most hiring managers expect. Increasing overall supply hasn't materially widened that subset. If anything, the influx of big pharma profiles makes it easier to make a poor hire that looks credible on paper.

The benchmark problem runs deeper than most organisations acknowledge. A CRA from a large CRO has been operating within a structure built specifically to support their function: SOPs for everything, a dedicated project management layer, therapeutic area specialists available internally, and clinical operations leadership who absorb the ambiguity before it reaches the team. Biotech removes most of that. A sponsor-side clinical operations hire in a growth-stage organisation is often asked to operate without that scaffolding, contribute to building the processes they'll eventually follow, and maintain trial quality while doing it.

When you benchmark against big pharma or CRO profiles, you optimise for the wrong things. Comfort with complexity gets outweighed by protocol adherence credentials. Autonomy under pressure becomes invisible next to breadth of experience across therapeutic areas. The hire you make might look like the right call until it isn't.

‍

What actually predicts success in the biotech context

The attributes that differentiate a strong sponsor-side clinical operations hire aren't obscure, but they require deliberate effort to surface in a standard process. Adaptability is the most frequently cited quality and also the most poorly assessed. Asking candidates whether they can adapt tells you very little. Asking them to walk through a specific moment where the ground shifted mid-trial, the infrastructure wasn't there, and they had to make a call without escalation routes available, that tells you considerably more.

Independence matters, but so does the specific type of independence. Someone who prefers to work without oversight because they've internalised a CRO-style process and want to execute it cleanly is different from someone who can hold ambiguity, reprioritise without prompting, and make reasonable decisions when the right answer isn't written down anywhere. Biotech needs the latter. The former is a risk, particularly in lean teams where misalignment compounds quickly.

Sponsor-side roles also demand a commercial sensitivity that CRO roles don't. CRAs in a CRO context operate within a defined service delivery framework. Sponsor-side, particularly in a biotech building towards data readouts or a financing milestone, the individual's decisions have visible consequences for the organisation's trajectory. Candidates who understand that, whether they've operated in that environment before or can demonstrate how they think about it, tend to integrate more effectively and move faster.

Interview processes that test for these qualities rarely look like standard competency-based formats. The companies that assess well tend to use structured scenario work, involve cross-functional interviewers who've worked in similar environments, and give candidates a genuine picture of the role's ambiguity upfront rather than presenting it as more structured than it is. That transparency also functions as a filter. The candidates who engage seriously with an honest brief tend to be the ones worth hiring.

‍

The cost of building under pressure

When clinical operations hiring starts late, the process compresses. There's less time for multiple interview rounds, less tolerance for extended offer deliberation, and less room to reopen a search if the first shortlist isn't right. All of that shifts leverage away from the hiring organisation and reduces the quality ceiling for the hire.

The financial case is straightforward. Clinical trials run on timelines with hard deadlines attached to financing events, regulatory submissions, and board milestones. A clinical operations function that's under-resourced at the point where momentum matters most doesn't just slow down, it introduces risk at the precise moments when the organisation can least absorb it.

The companies that build well tend to start conversations about their clinical operations structure six to nine months before they need the function in place, not six to nine weeks. That lead time allows for a genuine market assessment, a more deliberate interview process, and the kind of offer construction that reflects real knowledge of what comparable candidates are receiving. One anonymised biotech Vector Talent supported through a clinical operations build-out achieved a 100% offer acceptance rate across the function. That outcome doesn't happen by accident. It comes from understanding the candidate market before the process starts, moving decisively when the right profiles are identified, and not leaving gaps between assessment and offer that allow candidates to be pulled elsewhere.

For hiring managers working through this kind of build-out, understanding the biotech-specific candidate landscape is the starting point. What the broader pharma services market looks like matters far less than what the relevant subset looks like, and that picture changes quickly.

More on Vector Talent's work with growth-stage biotech organisations, including detail on how we've supported clinical function build-outs from early-stage through to late-phase, is available at vectorta.com/biotech.